you are viewing a single comment's thread.
Some findings for sure. Nov 8 (Reuters) - Novo Nordisk A/S : * Hypoglycemia risk of Novo nordisk's degludec insulin in trials did
not appear significantly higher or lower than oher insulins -- chair of FDA
advisory panel * Balance seemed reasonable between efficacy and hypoglycemia in studies of
degludec - chair of FDA advisory panel * 24-hr half life of degludec makes it unique in terms of long, stable
duration, dosing flexibility - chair of FDA advisory panel
Sentiment: Strong Buy